-transparent.png){kind=logo}
The value of the beryllium macrophage migration inhibition (Be MIF) and Mantoux tests in the diagnosis of chronic beryllium disease and in the detection of hypersensitivity in healthy beryllium workers is demonstrated. In the absence of steroid treatment the Be MIF test is positive in chronic beryllium disease patients. Seven of 50 (14%) helathy beryllium workers were Be MIF positive, while all the control subjects, normal and sarcoidosis patients, were negative. Healthy beryllium workers tend to be more often Mantoux negative than a comparable group of non-exposed workers, and although not conclusive this finding correlates with a positive Be MIF test. Although the detection of hypersensitivity is not diagnostic of disease, the Be MIF test can be used as an additional method for monitoring the health of beryllium workers. The full significance of our results should be assessed by a long-term study.
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
January 1983,
Thorax,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
October 1970,
The Journal of investigative dermatology,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
March 2009,
Current opinion in pulmonary medicine,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
January 1988,
Annual review of medicine,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
June 1982,
Journal of clinical pathology,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
March 1996,
Chest,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
August 2009,
Immunology and allergy clinics of North America,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
June 1997,
Journal of occupational and environmental medicine,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
January 1988,
Methods in enzymology,
C D Price, and
W J Williams, and
A Pugh, and
D H Joynson
January 2007,
ALTEX,
